GRIPP Coordinated Funding Call 1 2025

4 Sept 2025 - 14 Nov 2025

Last updated on 17 November 2025

Main points

Call Title: “Outbreak ready: Accelerating clinical trial site readiness in LMICs.”
Call budget: Up to 2 million euros
Grant Values: 100,000 to 500,000 euros
Duration of Supported Grants: Maximum duration 24 months
Call Submission Dates:
- Open: 4 Sept 2025
- Close: 14 Nov 2025

GRIPP 1 information webinar

An informational webinar was held on Monday, 13 October 2025 to provide a better understanding of what GRIPP 1 entails and to give an overview of the call, including eligibility criteria, application procedures and key steps after the submission deadline.

Open from 4 September to 14 November 2025, this call focuses on accelerating the preparation of clinical trial sites in low- and middle-income countries (LMICs). ANRS Emerging infectious diseases is one of the funders of this call.

Webinar replay

GloPID-R first joint call for proposals : GRIPP 1

GloPID-R is pleased to announce the first Global Research Improving Pandemic Preparedness (GRIPP) call for proposals: “Outbreak ready: Accelerating clinical trial site readiness in LMICs.”

The opening of GRIPP Call 1 marks a significant milestone in advancing the GloPID-R group of international research funders agreed aim to establish a coordinated research funding mechanism to strengthen global pandemic preparedness, which was launched in December 2024.

The Call 1 theme—strengthening the clinical research ecosystem in low- and middle-income countries (LMICs) to improve good clinical practices—was chosen by the GloPID-R Members in recognition of the pivotal role in building coordinated, equitable clinical trial capacity.

The call seeks to directly advance the World Health Organization’s (WHO) Global Action Plan for Clinical Trial Ecosystem Strengthening (GAP-CTS ) which delivers the commitments outlined by the World Health Assembly Resolution 75.8 and operationalizing the goals and principles of the GloPID-R Funders Living Roadmap for Clinical Trial Coordination.

As such we are inviting proposals that enhance clinical trial sites in line with the following GAP-CTS action areas:

Action 4: Enabling effective trials through adoption of innovative designs and digital technologies
Action 6: Improving coordination and streamline regulatory and ethics review
Action 9: Expanding international health research and clinical trial collaboration

Proposals funded through this call will leverage and extend existing GloPID-R member investments in clinical trial research in relevant topics in LMICs. The call underscores a shared commitment among international funders in countries around the world, through shared membership of the GloPID-R alliance, to work together to strengthen the enabling environment for clinical research, at the heart of pandemic preparedness efforts.

Frequent questions

Who is funding Call 1?

Call 1 is being funded by the following participating GloPID-R Members with delivery coordinated in partnership with the European and Developing Countries Clinical Trials Partnership (EDCTP) Association:

ANRS Maladies infectieuses émergentes (ANRS MIE) – France
Department of Health and Human Services (DHSC) – United Kingdom
Gates Foundation – United States
National Research Foundation (NRF) / Korea Research Institute of Bioscience & Biotechnology (KRIBB) – South Korea
South Africa Medical Research Council (SAMRC)– South Africa

Who is eligible for GRIPP Call 1?

Proposals must be submitted by a consortium of organizations (minimum 2, maximum 4) including:

One organization currently funded by an GloPID-R Member¹ to conduct a clinical trial(s) (phase I-III)² focused on (re-)emerging diseases of epidemic potential.³
1. The funder does not need to contribute to this call but must be one of the 35 GloPID-R members.
2. Clinical trial verification must be provided through a funding award letter and trial registration in a WHO-compliant registry.
3. Defined as high-priority pathogens outlined in the ‘Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness’ report
At least one organization from an LMIC
For proposals under Action 6 (Ethics), the consortium must include at least one legal entity hosting a national regulatory authority and/or ethics committee in the LMIC concerned.